08/19/2017 Conference IBDH Chicago 2017

It is the gathering of the top most renowned doctors in the field of IBD. It is an opportunity not to be missed where you can meet and discuss key topics with colleagues within a highly favored group of a 150-200 participants.

Generating Consensus in IBD 2017 Meeting offers you:

  • Relevant and engaging presentations by renowned speakers
  • A forum to collaborate with others and ask questions and share your experiences
  • A place to reflect upon and refine your own practices

August 19

8:00 am


  • Start: August 19 2017, 8:00 am
  • End: August 19 2017, 3:30 pm
  • Cost: FREE
  • Credits: CME 6 Credits


  • 172 W Adams Street / Chicago, IL 60603


Topic Speakers
Redefining Disease Severity in IBD Dr. Stephen Hanauer
Combination therapy once and for all
Monotherapy for the Masses
To treat on or not to treat post-operative Crohn’s Disease
Diagnosing and managing Short Bowl in IBD
Optimizing Biologic Therapies using Therapeutic Drug Monitoring
Top Down vs Step up therapy for IBD
Step up vs Top Down therapy for IBD
Perspectives on the medical pipeline


Learning Objectives

After completion of this activity, participants will be able to:

  1. Understand the severity definition to allow more formal management algorithms to be developed. This in turn would lead to more reliable data being reported in the literature, inevitably resulting in more effective surgical and pharmacotherapies to be delivered.
  2. Summarize the available evidence on where serological testing has the greatest benefit in the diagnostic algorithm of IBD.
  3. Analyze the effectiveness of biologics and predictors of response in order to optimize the management of patients with moderate-to-severe Crohn’s disease.
  4. Evaluate the available data on azathioprine and methotrexate in order to optimize their use in patients with steroid-refractory IBD.
  5. Assess the evidence regarding the role of therapeutic drug monitoring in order to optimize response to biologics in patients with IBD.
  6. Examine the efficacy and role of calcineurin inhibitors and biologics in patients with steroid-refractory ulcerative colitis.
  7. Apply the most recent evidence-based information regarding the reproductive safety of IBD therapies when counseling patients who are considering pregnancy or who are pregnant.
  8. Describe the available medical and surgical data concerning the treatment of patients with complex perianal CD.
  9. Evaluate the usage of chromoendoscopy for cancer surveillance of invisible dysplasia
  10. Evaluate new and emerging therapies for the management of IBD in order to respond to caregiver questions and to refer patients to clinical trials.



















CME Supporters

Target Audience


– Adult and pediatric gastroenterologists
– Advanced registered nurse practitioners
– Physician assistants
– Pharmacists providing care for IBD patients.

Statement of Need/Program Overview


The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons® is to provide healthcare providers the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants have been designed into the educational program.


6 CME Credits

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and IBD Horizons. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 6.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 6.0 contact hours (0.6 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-16-104-L01-P)

This is a knowledge based activity.